BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15487882)

  • 1. Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis.
    Nguyen TV; Dikun M
    Am J Health Syst Pharm; 2004 Sep; 61(18):1922-4. PubMed ID: 15487882
    [No Abstract]   [Full Text] [Related]  

  • 2. Alteplase use for clotted catheters.
    Macon EJ
    Semin Dial; 2002; 15(1):72. PubMed ID: 11874599
    [No Abstract]   [Full Text] [Related]  

  • 3. Managing catheter dysfunction for better patient outcomes: a team approach.
    Dinwiddie LC
    Nephrol Nurs J; 2004; 31(6):653-60, 671; quiz 661-2. PubMed ID: 15686329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
    Little MA; Walshe JJ
    Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review.
    Hilleman D; Campbell J
    Pharmacotherapy; 2011 Oct; 31(10):1031-40. PubMed ID: 21950645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters.
    Dowling K; Sansivero G; Stainken B; Siskin G; Dolen E; Ahn J; Mitchell N
    Nephrol Nurs J; 2004; 31(2):199-200. PubMed ID: 15114800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.
    Vercaigne LM; Zacharias J; Bernstein KN
    Clin Nephrol; 2012 Oct; 78(4):287-96. PubMed ID: 22541682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using alteplase to clear occlusions.
    Moureau N
    Nursing; 2002 Jan; 32(1):73. PubMed ID: 12926500
    [No Abstract]   [Full Text] [Related]  

  • 9. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
    Ponce D; Mendes M; Silva T; Oliveira R
    Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
    Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
    N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteplase for the treatment of catheter occlusion in pediatric patients.
    Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
    Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
    Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
    J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tesio twin catheter system for hemodialysis tunnelized using an echo-guided technique. Retrospective analysis of 210 catheters].
    Ibrik O; Samon R; Roca R; Viladoms J; Mora J
    Nefrologia; 2006; 26(6):719-25. PubMed ID: 17227250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of rt-PA infusion in tunnelled dialysis catheters.
    Davies J; Casey J; Li C; Crowe AV; McClelland P
    EDTNA ERCA J; 2005; 31(2):75-8. PubMed ID: 16180551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Rescue Utilization of Intraoperative Tissue Plasminogen Activator in the Setting of Massive Thrombosis of Avalon Catheter and Patient in Extremis with Refractory Hypoxemia.
    Martin AK; Allen WL; Fritz AV; Diaz-Gomez JL
    J Cardiothorac Vasc Anesth; 2018 Oct; 32(5):2278-2281. PubMed ID: 29395819
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters.
    Daeihagh P; Jordan J; Chen J; Rocco M
    Am J Kidney Dis; 2000 Jul; 36(1):75-9. PubMed ID: 10873875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
    Eyrich H; Walton T; Macon EJ; Howe A
    Am J Health Syst Pharm; 2002 Aug; 59(15):1437-40. PubMed ID: 12166043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dialysis catheters and recombinant tissue plasminogen activator.
    Allon M
    N Engl J Med; 2011 May; 364(18):1779; author reply 1779-80. PubMed ID: 21542758
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
    Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
    J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.